Biotechnology from bench to business

• Follow GEN on:
• Login | Register | Subscribe

• ADME/Tox
• Automation
• Bioprocess Scale-Up
• Bioreactors
• Biosimilars
• Cell Culture
• Cell-Based Assays
• Contract Manufacturing
• Gene Therapy
• High-Throughput Screening
• Immunoassay
• Induced Pluripotent Stem Cells
• Informatics
• Liquid Handling
• Protein Characterization
• Protein Detection
• Regenerative Medicine
• RNAi/siRNA
• Stem Cells
• Western Blot

• GEN Articles

• More »

• Feature Articles: Pooling Knowledge for Neglected Diseases
  Open Innovation Provides Access to IP to Save Lives in the Developing World

• Insight & Intelligence™

• More »

• Despite Flat Budget, NIH’s TRND Program Tries to Spark Interest in Rare and Neglected Diseases
  January 31, 2012
  With 14 approved programs in total, TRND has progressed two into clinical development.

• GEN News Highlights

• More »

• Wellcome Trust Awards University of Dundee, GSK £8.6M for Tropical Disease Therapies
  
• NIH’s TRND Program Will Boost Rare and Neglected Disease Drug Development, GEN Voters Say
  
• Private-Public Partnership Focusing on Neglected Tropical Diseases Established
  
• FDA Clears Abbott’s Confirmatory Chagas Disease Assay
  
• United Therapeutics Wins NIAID Contract Worth $45M to Develop Broad-Spectrum Antiviral Drug
  

• GEN Podcasts

• More »

• GRANDRx—Mission, Goals, and Challenges
  Interview with Patrick Terry, Acting CEO of the Grand Therapeutics Foundation, and Christopher Austin, M.D., Director of the NIH Chemical Genomics Center, and Member, Editorial Board, ASSAY and Drug Development Technologies.